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Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use
Eliza A. Dy, Dane L. Shiltz
Abstract
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran.
CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough,
fatigue, and bloody stools. The patient had a large hyperdense pericardial effusion caused by
accumulation of bloody fluid, leading to hypotension and shock. Approximately 1000 mL of hemorrhagic
fluid was drained from the pericardial space. A 77-year-old female was admitted for treatment of
pneumonia and atrial fibrillation. Dabigatran was initiated and, after 6 doses, the patient developed
abdominal pain, respiratory distress, and shock. She was diagnosed with pericardial effusion leading to
cardiac tamponade. Pericardiocentesis and thoracentesis procedures removed a cumulative total of 2000
mL of bloody fluid.
DISCUSSION: Dabigatran is an oral direct thrombin inhibitor approved for the reduction of stroke and
systemic embolism risk in patients with nonvalvular atrial fibrillation. In December 2011, the Food and
Drug Administration released a statement describing serious bleeding events associated with dabigatran
use. According to the Naranjo scale, the cases presented here had probable associations between
hemopericardium and dabigatran. While there is no known literature supporting this relationship, there
are documented cases of warfarin-induced hemopericardium.
CONCLUSIONS: These case reports highlight the potential for dabigatran to cause hemopericardium
and cardiac tamponade. Additional reports may better elucidate (or characterize) the risk of dabigatraninduced hemopericardium and cardiac tamponade.

Dabigatran is an oral direct thrombin inhibitor approved by the Food and Drug Administration
(FDA) in 2010 for the reduction of stroke and systemic embolism risk in patients with
nonvalvular atrial fibrillation.1 Dabigatran competitively inhibits thrombin, thereby preventing
the conversion of fibrinogen to fibrin, a necessary step in the formation of a thrombus.
Dabigatran, similar to the intravenous direct thrombin inhibitor argatroban, can increase the
international normalized ratio (INR); however, due to the unpredictable nature of INR results
with dabigatran use, it is generally recommended to avoid routine INR monitoring.1,2
In December 2011, the FDA released a statement describing a postmarketing evaluation of
serious bleeding events associated with dabigatran use.3 One of these potential bleeding events is
hemopericardium. Hemopericardium is defined as a collection of hemorrhagic fluid in the
pericardial space.4 Large amounts of fluid in this space can lead to cardiac tamponade, an acute
increase in pressure and cardiac compression.4 We describe 2 patients who experienced these
serious adverse events following treatment with dabigatran.
Case Reports
CASE 1

A 70-year-old white male presented to the emergency department (ED) on June 25, 2011,
reporting 7 days of mild cough and fatigue and 1 day of bloody stools. The patient had a history
of atrial fibrillation and was receiving anticoagulation therapy for primary stroke prevention
(CHADS2 score = 3). In addition to atrial fibrillation, the patient's history was significant for
chronic left ventricular systolic dysfunction with an ejection fraction (EF) of 45% in July 2010,
stage 3 diastolic dysfunction, chronic kidney disease stage 3 (baseline serum creatinine 1.1
mg/dL, baseline estimated creatinine clearance 66 mL/min), type 2 diabetes mellitus,
hypertension, hyperlipidemia, osteoarthritis, benign prostatic hypertrophy, peripheral vascular
disease, and gout. The patient had been admitted twice in the 3 months leading to this event,
once for generalized weakness and once for hypoglycemia, at which times he had stable serum
creatinine concentrations of 1.04 mg/dL (creatinine clearance [CrCl] 70 mL/min) and 1.17
mg/dL (CrCl 64 mL/min).
Since August 2010, the patient had received warfarin. For a reason not clearly indicated in the
patient's medical history, therapy was switched from warfarin to oral dabigatran 150 mg twice
daily in March 2011. At that time, the patient was also receiving chronic antiplatelet therapy with
aspirin 81 mg daily. Additionally, the medication reconciliation history revealed that the patient
began taking pantoprazole 40 mg daily sometime after initiation of dabigatran therapy.
Laboratory results upon admission revealed an elevated serum creatinine concentration of 6.26
mg/dL (estimated CrCl of 11 mL/min) and serum potassium concentration of 8.2 mEq/L. The
INR was greater than 6. He reported adherence to dabigatran and confirmed that he had not been
taking warfarin. The patient's weight upon presentation was 109 kg. A Hemoccult stool test in
the ED was positive, and hemoglobin and hematocrit were 10.9 g/dL and 33.7%, respectively;
these values did not significantly differ from baseline values (10-11 g/dL and 33-34%) found in
previous admission records. While the patient was in the ED on June 25, a left pleural effusion
was observed on chest X-ray and was confirmed by bedside ultrasound performed shortly after
admission. The patient was admitted for treatment of suspected septic shock, acute-on-chronic
renal failure, and coagulopathy. Dabigatran was discontinued upon admission.
On the evening of June 25, the patient was intubated for respiratory failure. Intravenous broadspectrum antibiotic therapy with vancomycin, piperacillin/tazobactam, and azithromycin was
continued to treat possible infectious etiologies of shock, including pneumonia. Blood cultures
obtained on June 25 did not reveal bacterial growth. The patient continued treatment with
vasopressin and norepinephrine for hypotension, with limited improvement in blood pressure.
A computed tomography (CT) image of the chest, performed on June 26, did not reveal findings
of pneumonia but rather a large hyperdense pericardial effusion. An emergent pericardiocentesis
was performed by a consulting cardiologist to treat the cardiac tamponade. Approximately 1000
mL of hemorrhagic fluid was drained from the pericardial space, resulting in improved
hemodynamics and gradual weaning of vasopressors. Hemoglobin decreased to 6.7 g/dL
following removal of the hemorrhagic fluid, and the patient required transfusion of 2 units of
packed red blood cells (PRBCs).

On June 27, the critical care team acknowledged that this hemorrhagic pericardial effusion was
likely the cause of the patient's hypotension and shock and was likely due to “dabigatran in the
setting of chronic kidney disease… contributing to an increased risk of bleeding.”
The patient was discharged after 17 days and was transferred to a subacute rehabilitation facility,
at which time stroke prevention with warfarin was restarted.
CASE 2
A 77-year-old African American female presented to the ED on May 12, 2011, with dizziness,
shortness of breath, incontinence, and cough. The patient had been discharged for a diagnosis of
pneumonia on April 27 and again on May 1. The patient was admitted on both of these dates.
She was prematurely discharged the first time, which led to readmission on May 1 for unresolved
pneumonia. Her history at the time of the current admission was significant for chronic
obstructive pulmonary disease, pulmonary hypertension, hypertension, left ventricular systolic
dysfunction with an EF of 40% in June 2010 (via 2-dimensional echocardiogram),
gastroesophageal reflux disease, coronary artery disease, anemia, chronic kidney disease stage 3
(baseline serum creatinine 1.2 mg/dL, baseline estimated CrCl 28 mL/min), dyslipidemia,
hypothyroidism, hemorrhoids, and diverticulosis. The patient's pertinent home medications
included aspirin 81 mg once daily.
Initial evaluation in the ED revealed an elevated white blood cell count (14.7/μL), and a chest Xray revealed left lower lobe opacities and resolution of the right lower lobe opacities for which
she had previously been treated. Serum creatinine upon admission in the ED was consistent with
a baseline value of 1.22 mg/dL and an estimated CrCl of 28 mL/min. INR on admission was
1.21, hemoglobin was 11.6 g/dL, and weight was 55 kg. The patient was found to have atrial
fibrillation, with heart rates of 86-136 beats/min. An electrocardiogram performed in the ED
demonstrated a ventricular rate of 134 beats/min and an atrial rate of 134 beats/min; this was
interpreted as “atrial fibrillation with rapid ventricular response. … When compared with
electrocardiogram of May 2, 2011, [it shows that] atrial fibrillation has replaced sinus rhythm.”
The patient was consequently admitted for treatment of health care–associated pneumonia
(HCAP) and atrial fibrillation.
In addition to beginning treatment for HCAP with piperacillin/tazobactam and vancomycin, newonset atrial fibrillation workup continued following admission. A cardiology consult to evaluate
the patient was conducted on May 17, and need for anticoagulation was discussed (CHADS2
score = 3). At that time, dabigatran 150 mg twice daily was initiated, with the first dose
administered later that evening.
On May 20, the patient developed respiratory distress and severe abdominal pain. She was
subsequently transferred to the intensive care unit. Soon thereafter she developed shock,
requiring intubation and treatment with intravenous 0.9% NaCl, dopamine, and norepinephrine.
Infectious diseases consultants recommended empiric treatment with linezolid and meropenem to
rule out infectious causes; these were later discontinued when there was no bacterial growth in
blood cultures. A 2-dimensional echocardiogram performed later that day showed a moderately
sized pericardial effusion with right ventricular diastolic compression, leading to cardiac

tamponade. At this time, aspirin and dabigatran were discontinued. At the time of
discontinuation, the patient had received a total of 6 doses of dabigatran 150 mg.
A cardiologist immediately performed pericardiocentesis, which led to the removal of
approximately 400 mL of bloody pericardial fluid. Cultures taken from fluid samples did not
indicate infectious involvement. An echocardiogram following the procedure confirmed minimal
fluid residuals. Following this procedure, the patient was weaned from vasopressors. After
pericardiocentesis, the hemoglobin and hematocrit decreased (7.6 g/dL and 23.9%, respectively),
necessitating transfusion with 2 units of PRBCs. Cardiogenic rather than septic shock was
thought to be the likely cause of the patient's decline.
A chest X-ray taken on May 21 revealed a new right pleural effusion. A thoracentesis performed
on May 22 removed approximately 400 mL of bloody fluid. Again, the patient's hemoglobin
decreased to 7.5 g/dL and hematocrit decreased to 22.8% following removal of the fluid, and an
additional 2 units of PRBCs were administered. The patient received 4 more units of PRBCs
within the following 7 days.
Meanwhile, the patient's renal function continued to decline (Table 1). Concerns regarding
overanticoagulation from dabigatran secondary to acute renal failure were discussed by
consulting nephrologists and hematologists. Acute renal failure necessitated the initiation of
hemodialysis beginning on May 24. A consulting nephrologist expressed hope that dialysis
would help remove dabigatran and therefore resolve the coagulopathy.
A chest X-ray performed following another acute respiratory decompensation on May 29,
however, revealed development of a new left pleural effusion. Thoracentesis on May 29 removed
approximately 1200 mL of bloody fluid. The critical care physicians who performed the
procedure noted that the fluid from May 29 was significantly bloodier than that from May 22. A
repeat 2-dimensional echocardiogram on May 29 revealed resolution of the pericardial effusion.
Dabigatran was identified as the most likely cause of coagulopathy in this patient. The course of
events by which dabigatran led to cardiac tamponade and acute renal failure versus acute renal
failure leading to dabigatran toxicity and cardiac tamponade remains unclear.
The patient was discharged without anticoagulation for stroke prevention to a long-term acute
care facility after a 1-month stay in the intensive care unit. She died a few months later because
of respiratory failure.

Table 1. Case Report 2: Serum Creatinine Values Relative to
Dabigatran Doses.

Date
5/12
5/13
5/14
5/15
5/16
5/17
5/18
5/19
5/20
5/21
5/22
5/23
5/24

Serum
Creatinine
(mg/dL)
1.22
1.21
1.37
1.26
0.99
0.99
0.99

Estimated Creatinine
Clearance (mL/min)
28
28
24
27
34
34
34

1.07
1.46
1.84
2.34
2.64
3.20
2.93
4.02
4.24

32
23
18
14
13
11
12
8
8

Dabigatran
Dose (mg)

150
150
150
150
150
150

Discussion
The 2 cases presented here may demonstrate dabigatran's potential to cause serious bleeding
events, particularly in the setting of acute renal failure. According to the FDA-approved dosing,
dabigatran should be decreased to 75 mg by mouth twice daily for patients with a CrCl of 15-30
mL/min. For patients with severe renal dysfunction, dabigatran should not be used, as there are
no dosing recommendations for this population. Both patients in this report were started on
dabigatran 150 mg twice daily. At the time that hemopericardium occurred, both patients were
experiencing acute renal failure, with CrCl values less than 15 mL/min. The use of dabigatran
150 mg in the setting of acute renal failure likely contributed to increased drug accumulation and
increased risk of serious bleeding events. Additionally, it does not appear that periodic renal
monitoring, as is currently recommended by the manufacturer, was performed in the first patient;
these events occurred in both patients prior to publication of this renal monitoring
recommendation.1
Spontaneous, nontraumatic hemopericardium, as described in these 2 cases, has an incidence of
2.5-11% in patients receiving any form of anticoagulation.5,6 Patients who progress to the
development of cardiac tamponade require immediate intervention to remove the fluid via
pericardiocentesis.4
According to the Naranjo probability scale, each of the cases outlined in this report had a
probable association between hemopericardium and dabigatran use.7 While there is no known
literature, and only one published case report8 outlining the relationship between
hemopericardium and dabigatran use, there are a handful of documented cases of warfarininduced hemopericardium.8–11 At the time of writing, we identified 10 published case reports of
warfarin-induced hemopericardium and cardiac tamponade.9–11

Katis reported a 67-year-old female who presented to the ED in 2005 with sudden new-onset
chest pain.9 The patient had experienceed a pulmonary embolus 3 weeks prior to presentation,
and she had subsequently received anticoagulation therapy with warfarin. Her INR upon
admission was 3.51. A CT image revealed pericardial effusion, and pericardiocentesis removed
400 mL of blood. A pericardial drain led to the removal of an additional 600 mL of blood.
Hong et al. described a case of a 70-year-old male who presented to the ED in 2007 with
progressive dyspnea and orthopnea.10 The patient's history was significant for a mitral valve
replacement 12 years prior to admission, and he was receiving warfarin. His INR upon admission
was 7.52. An echocardiogram revealed cardiac tamponade, which led to 400 mL of blood being
drained via pericardiocentesis. An emergency pericardiotomy removed an additional 1300 mL of
dark blood.
Levis et al. reported a case of a 54-year-old male who presented to the ED in 2009 following a
syncopal episode.11 His history was significant for atrial fibrillation for which he received
chronic warfarin therapy. The patient's INR upon admission was 6.0. A bedside cardiac
ultrasound revealed a cardiac effusion. A portable echocardiogram revealed a cardiac
tamponade, leading to a pericardiocentesis that removed 1100 mL of blood.
In 2012, Barton et al. did report a case of hemopericardium in a patient taking dabigatran.8 A 70year-old male presented to an outpatient pulmonologist office with complaints of increasing
shortness of breath. His history was significant for atrial fibrillation and anticoagulation with
dabigatran for 2 months. A CT scan revealed a large pericardial effusion, and the patient was
emergently sent to the ED. Upon admission, his serum creatinine concentration was 1.49 mg/dL
with an estimated CrCl of 43 mL/min. Pericardiocentesis later removed 1250 mL of bloody fluid,
and the patient was discharged without anticoagulation after 4 days.
These cases raise concern regarding the impact that oral anticoagulants can have on development
of hemopericardium and cardiac tamponade. Clinical studies are needed to establish the risk
factors between individual anticoagulants and potential for hemopericardium.
This report highlights the potential for dabigatran to cause hemopericardium and cardiac
tamponade. Additional reports of hemopericardium associated with dabigatran may help to
clarify the true risk of this life-threatening condition.
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